Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
3.5
Expiration
Nov 6, 2026
DTE
17d
Moneyness
ITM
Intrinsic
$4.86
IBRX 3.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $6.49 | -0.61% | 1 | 17 |
| Oct 30, 2026 | 10d | $5.80 | +20.83% | 2 | 6 |
| Nov 6, 2026 | 17d | $6.60 | +3.45% | 8 | 24 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $6.54 | -7.23% | 4 | 4,158 |
| Jan 21, 2028 | 458d | $7.10 | +1.87% | 10 | 27,275 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.